Sichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions

Simply Wall St.08-18

Investors pushed Sichuan Kelun-Biotech Biopharmaceutical up to HK$542.5 by Monday’s close, after a strong run over the past quarter, yet the fresh numbers tell a more complicated story than the price ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2660464776?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-08-18 18:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660464776","market":"nz","top_or_hot":-1,"title":"Sichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions","media":"Simply Wall St.","content":"<div>\n<p>Investors pushed Sichuan Kelun-Biotech Biopharmaceutical up to HK$542.5 by Monday’s close, after a strong run over the past quarter, yet the fresh numbers tell a more complicated story than the price ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-stock-rebound-meets-profit-qu\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun-Biotech (SEHK:6990) Stock Rebound Meets Profit Quality Questions\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-18 18:31 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-stock-rebound-meets-profit-qu><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Investors pushed Sichuan Kelun-Biotech Biopharmaceutical up to HK$542.5 by Monday’s close, after a strong run over the past quarter, yet the fresh numbers tell a more complicated story than the price ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-stock-rebound-meets-profit-qu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06990","symbol_name":"科伦博泰生物","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-stock-rebound-meets-profit-qu","article_id":"2660464776","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-sehk6990-stock-rebound-meets-profit-qu","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2660464776","pubTimestamp":1787049091,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Investors pushed Sichuan Kelun-Biotech Biopharmaceutical up to HK$542.5 by Monday’s close, after a strong run over the past quarter, yet the fresh numbers tell a more complicated story than the price chart alone. The emotional hook is clear: H1 2026 swung back to profit with basic earnings per share of CN¥1.66 and net income of CN¥388.01m, a sharp contrast to the losses booked through 2025. The question is whether this return to the black justifies the rich P/B multiple and elevated...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"06990":"科伦博泰生物","BK4585":"ETF&股票定投概念","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK4588":"碎股","BK1161":"生物科技"},"translate_title":"四川科伦生物（SEHK:6990）股票反弹遇到利润质量问题","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"06990":0.9},"content_text":"Investors pushed Sichuan Kelun-Biotech Biopharmaceutical up to HK$542.5 by Monday’s close, after a strong run over the past quarter, yet the fresh numbers tell a more complicated story than the price chart alone. The emotional hook is clear: H1 2026 swung back to profit with basic earnings per share of CN¥1.66 and net income of CN¥388.01m, a sharp contrast to the losses booked through 2025. The question is whether this return to the black justifies the rich P/B multiple and elevated expectations already baked into the stock. Is Sichuan Kelun-Biotech Biopharmaceutical a rare growth story trading at a discount, or is the rich P/B multiple already doing the heavy lifting? Compare the DCF, peer multiples and growth assumptions in our valuation analysis for Sichuan Kelun-Biotech Biopharmaceutical AdvertisementH1 2026 Earnings Summary  Revenue (H1 2026 vs. H1 2025): CN¥978.34m vs. CN¥950.45m (stable to modest growth) Net Income (Excl. Extra Items, H1 2026 vs. H1 2025): profit of CN¥388.01m vs. loss of CN¥145.18m (swing back to profit) Basic EPS (H1 2026 vs. H1 2025): CN¥1.66 per share vs. loss of CN¥0.64 per share (return to positive earnings per share) Trailing 12 Month Net Income (Excl. Extra Items, to H1 2026 vs. to H1 2025): profit of CN¥151.21m vs. loss of CN¥722.17m (movement from loss to profit over the last year, including a one off gain of CN¥52.7m)  Prefer clean charts instead of another wall of financial tables and footnotes? See Sichuan Kelun-Biotech Biopharmaceutical’s full visual breakdown, with a focus on valuation and how the current share price lines up, in our company report for Sichuan Kelun-Biotech Biopharmaceutical. SEHK:6990 Trailing 12-Month Earnings & Revenue History as at Aug 2026 Sichuan Kelun-Biotech: Bull Story Faces First Real Test Bulls argue that Sichuan Kelun-Biotech is turning clinical momentum in ADCs, or antibody drug conjugates, into a high quality earnings ramp. The latest half gives some support to that view. Net income excluding extra items moved to a CN¥388.01m profit in H1 2026, compared with a loss in H1 2025. Earnings per share also moved back into positive territory at CN¥1.66. That shift aligns with the idea that sacituzumab tirumotecan and the broader late stage pipeline are starting to translate into better economics. The trailing 12 month figure, now a CN¥151.21m profit including a CN¥52.7m one off gain, shows that this is more than a single quarter blip, although part of the improvement is non recurring. Revenue at CN¥978.34m versus CN¥950.45m in H1 2025 looks steady, which supports a gradual build rather than a sudden product cliff. Bear Case Questions Quality and Durability Of Profit The bear view is that Kelun-Biotech leans heavily on partnered milestones and one off items while underlying profitability stays fragile. The latest numbers give that argument some fuel. The trailing 12 month profit of CN¥151.21m includes a CN¥52.7m one off gain. Strip that out and the margin picture looks thinner. Revenue moved to CN¥978.34m from CN¥950.45m in the half, which is solid but not a breakout that clearly reflects the breadth of the sacituzumab tirumotecan and RET franchise headlines. The sharp move from a CN¥145.18m loss in H1 2025 to a CN¥388.01m profit in H1 2026 will raise the question of how much is operational leverage versus mix effects and milestone timing. With 17 global Phase III trials and multiple new indications in asthma and COPD, bears will argue that execution risk and future cost intensity remain meaningful despite this profit print. High reported earnings quality often masks concentration risks in product economics and milestone timing. Review our independent risk analysis for Sichuan Kelun-Biotech Biopharmaceutical which shows 1 important warning sign to see whether this swing to profit is just the tip of the iceberg. Stay Ahead Of Your Next Move If the swing back to profit at Sichuan Kelun-Biotech Biopharmaceutical has your attention, register for free with Simply Wall St and add it to a Watchlist so you can track price against fair value and wait for a setup that fits your plan. After you decide to take a position, use the Portfolio Command Center to cut through noise and focus on essential portfolio level alerts. For longer term conviction, tap into the crowd insight inside the Community to see how other investors are thinking about the same risks and potential catalysts. This way you identify both upside triggers and early warning signs sooner and give yourself a better chance of staying ahead of the market. Seeking Alternatives Beyond Sichuan Kelun-Biotech? The best ideas often move first. Fresh stock themes can start to break out while attention stays locked on Sichuan Kelun-Biotech Biopharmaceutical. Spot what others miss before the crowd and act now.  Scan for steady compounders with strong balance sheets and earnings power by reviewing our curated list of solid balance sheet and fundamentals stocks (434 results) while these companies are still under the radar for now. Catch early momentum in companies involved in the AI infrastructure build out by using the hand picked 56 AI infrastructure stocks before valuations fully reflect any shifts in market attention. Prepare for potential capital rotations into metal producers by checking the focused 28 best rare earth metal stocks while these opportunities remain between specialist and mainstream attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660464776","isCrawlerRequest":true}